160 related articles for article (PubMed ID: 33081987)
21. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
22. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Tremblay MR; Poirier D
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
[TBL] [Abstract][Full Text] [Related]
23. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
Cortés-Benítez F; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
[TBL] [Abstract][Full Text] [Related]
24. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
26. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
27. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and preliminary evaluation of a modified estradiol-core bearing a fused γ-lactone as non-estrogenic inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
Ouellet E; Ayan D; Poirier D
Bioorg Med Chem Lett; 2011 Sep; 21(18):5510-3. PubMed ID: 21782424
[TBL] [Abstract][Full Text] [Related]
29. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ
Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457
[No Abstract] [Full Text] [Related]
30. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
[TBL] [Abstract][Full Text] [Related]
31. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
32. Chemical synthesis, characterisation and biological evaluation of lactonic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Farhane S; Fournier MA; Poirier D
J Steroid Biochem Mol Biol; 2013 Sep; 137():322-31. PubMed ID: 23685015
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2.
Al-Soud YA; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Arch Pharm (Weinheim); 2012 Aug; 345(8):610-21. PubMed ID: 22532378
[TBL] [Abstract][Full Text] [Related]
34. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
35. Chemical synthesis, characterisation and biological evaluation of furanic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Farhane S; Laplante Y; Poirier D
Med Chem; 2011 Mar; 7(2):80-91. PubMed ID: 21222612
[TBL] [Abstract][Full Text] [Related]
36. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
37. Chemical synthesis of the 17-propanamide derivatives of stereoisomeric Δ14-17α- and 17β-estradiols: potential 17β-hydroxysteroid dehydrogenase inhibitors.
Iida T; Ogawa S; Tamegai H; Adachi Y; Saito H; Ikegawa S; Konishi H; Takagi A; Matsuzaki T
Chem Phys Lipids; 2011 Feb; 164(2):106-12. PubMed ID: 21129370
[TBL] [Abstract][Full Text] [Related]
38. Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity.
Maltais R; Trottier A; Barbeau X; Lagüe P; Perreault M; Thériault JF; Lin SX; Poirier D
J Steroid Biochem Mol Biol; 2016 Jul; 161():24-35. PubMed ID: 26519987
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of substituted 15β-alkoxy estrone derivatives and their cofactor-dependent inhibitory effect on 17β-HSD1.
Herman BE; Kiss A; Wölfling J; Mernyák E; Szécsi M; Schneider G
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1271-1286. PubMed ID: 31307240
[TBL] [Abstract][Full Text] [Related]
40. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
